Title : Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS.

Pub. Date : 2014 Mar

PMID : 24378831






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Sorafenib, an inhibitor of a number of kinases targeting the Raf/MEK/ERK pathway, is a promising new chemotherapeutic agent in human medicine that has been approved since 2006 for the therapy of renal cell carcinoma and since 2007 for the treatment of hepatocellular carcinoma. Sorafenib zinc fingers and homeoboxes 2 Homo sapiens